Sun Pharmaceutical

Novo Nordisk's India team pushes for an earlier launch of Wegovy, fearing to fall behind Eli Lilly in the weight-loss market. Novo plans to introduce Wegovy in India in 2026, but the India team proposed a 2024 launch. Novo received regulatory approval for injectable semaglutide in India in late 2022.

DelveInsight's report on the Acute Ocular Pain Market forecasts significant growth (2020-2034) in the US, EU4, UK, and Japan. Key companies include Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma, Ocular Therapeutix, Kala Pharmaceuticals, and Bausch & Lomb. Recent FDA approvals and ongoing research are driving market dynamics, with treatments like DEXTENZA, INVELTYS, and LOTEMAX SM addressing post-operative pain. The market is expected to surge due to increasing prevalence and pipeline product launches.

DelveInsight's 'Epilepsy Pipeline Insight, 2024' report details 75+ companies developing 90+ therapies, including RLS103, CT-010, EQU 001, and others, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Novartis, Pfizer, Sanofi, and Takeda, among others.